Myelofibrosis: an update on current pharmacotherapy and future directions

Bibliography

• Tefferi A, Thiele J, Orazi A, Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007;31:737-40
   PubMed Web of Science ®Google Scholar
• Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189-94
   PubMed Web of Science ®Google Scholar
• Buschle M, Janssen JW, Drexler H, Evidence of pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988;2:658-60
   PubMed Web of Science ®Google Scholar
• Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-70
   PubMed Web of Science ®Google Scholar
• Kralowics R, Passamonti F, Buser AS, A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:1140-51
   Web of Science ®Google Scholar
• Milosevic JD, Kralowics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho T, Jimma T, One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012;87:25-33
   PubMed Web of Science ®Google Scholar
• Tam CS, Nussenzveig RM, Popat U, The natural history and treatment outcome of blast-phase BCR-ABL-negative myeloproliferative neoplasms. Blood 2008;112:1628-37
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-01
   PubMed Web of Science ®Google Scholar
• Ballen KK, Shrestha S, Sobocinski KA, Outcome of transplantation for myelofibrosis. Biol Bone Marrow Transplant 2010;16:358-67
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Passamonti F, Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012;30:2981-7
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, Activating mutation in the tyrosine kinase JAK2 in polychytemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573-82
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Biamonte F, Score J, EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011;118:5227-34
   PubMed Web of Science ®Google Scholar
• Brecqueville M, Rey J, Bertucci F, Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Gen Chromosome Cancer 2012;51:743-55
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Pardanani A, Bernard OA, Unraveling rhe genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th international post-ASH symposium. Am J Hematol 2012;87:562-8
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011;96:1398-402
   PubMed Web of Science ®Google Scholar
• Lasho TL, Jimma T, Finke CM, SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168-71
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D, Bone marrow pathology in essential thrombocythemia: inter-observer reliability and utility for identifying disease subtypes. Blood 2008;111:60-70
   PubMed Web of Science ®Google Scholar
• Buhr T, Hebeda K, Kaloutsi V, European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97:360-5
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1,104 patients. J Clin Oncol 2011;29:3179-84
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-8
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi A, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the International Working Group for Myeloproliferative Neoplasms Research and Treatment. Blood 2010;115:1703-8
   PubMed Web of Science ®Google Scholar
• Gangat N, Pardanani A, Hanson CA, DIPSS-Plus: a refined dynamic international prognostic scoring system(DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 2011;29:392-7
   PubMed Web of Science ®Google Scholar
• Martinez-Trillos A, Gaya A, Maffioli M, Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, Philadelphia–negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70
   PubMed Web of Science ®Google Scholar
• Hast R, Engstedt L, Jameson S, Oxymetholone treatment in myelofibrosis. Blut 1978;37:19-26
   PubMedGoogle Scholar
• Brubaker LH, Briere J, Laszlo J, Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 1982;142:1533-7
   PubMedGoogle Scholar
• Cervantes F, Alvarez-Larran A, Domingo A, Efficacy and tolerability of danazol as a treatment for the anemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771-5
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127:399-03
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Efficacy and safety of darbepoetin-alpha in the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006;134:184-6
   PubMed Web of Science ®Google Scholar
• Barosi G, Elliott M, Canepa M, Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from 5 studies. Leuk Lymph 2002;43:2301-7
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-41
   PubMed Web of Science ®Google Scholar
• Abgrall JF, Guibaud I, Bastie JN, Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006;91:1027-32
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cortes J, Verstovsek S, Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-64
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Manshouri T, Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-6
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yao X, Li CY, Lenalidomide and prednisone for myelofibrosis: eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436-9
   PubMed Web of Science ®Google Scholar
• Oishi N, Swisher SN, Troup SB. Busulfan therapy in myeloid metaplasia. Blood 1960;15:863-72
   PubMed Web of Science ®Google Scholar
• Petti MC, Latagliata R, Spadea T, Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;116:576-81
   PubMed Web of Science ®Google Scholar
• Tefferi A, Silverstein MN, Li C-Y. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997;99:352-7
   PubMed Web of Science ®Google Scholar
• Tefferi A, Mesa RA, Nagomey DN, Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000;95:2226-33
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cervantes F, Bruguera M, Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 1991;85:184-8
   PubMed Web of Science ®Google Scholar
• Chaffanjon PC, Brichon PY, Ranchoup Y. Portal vein thrombosis following splenectomy for hematologic disease: retrospective study with Doppler color flow imaging. World J Surg 1998;22:1082-6
   PubMed Web of Science ®Google Scholar
• Bouabdallah R, Coso D, Gonzague-Casabianca L, Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leuk Res 2000;24:491-5
   PubMed Web of Science ®Google Scholar
• Koeffler HP, Cline MJ, Golde DW. Splenic irradiation in myelofibrosis: effect on circulating myeloid progenitor cells. Br J Haematol 1979;43:69-77
   PubMed Web of Science ®Google Scholar
• Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-11
   PubMed Web of Science ®Google Scholar
• Barlett RP, Greipp PR, Tefferi A, Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 1995;70:1161-4
   PubMed Web of Science ®Google Scholar
• Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;118:813-16
   PubMed Web of Science ®Google Scholar
• Guardiola P, Anderson JE, Bandini G, Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999;93:2831-8
   PubMed Web of Science ®Google Scholar
• Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia (letter). N Engl J Med 2000;343:59
   Google Scholar
• Ballen KK, Shrestha S, Sobocinski KA, Outcome of transplantation for myelofibrosis. Biol Bone Marrow Transplant 2010;16:358-67
   PubMed Web of Science ®Google Scholar
• Scott BL, Gooley TA, Sorror ML, The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012;119:2657-64
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Gooley TA, Flowers ME, Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003;102:3912-18
   PubMed Web of Science ®Google Scholar
• Cervantes F, Rovira M, Urbano-Ispizua A, Remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic stem cell transplantation. Bone Marrow Transplant 2000;26:697-9
   PubMed Web of Science ®Google Scholar
• Devine SM, Hoffman R, Verma A, Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002;99:2255-8
   PubMed Web of Science ®Google Scholar
• Kroger N, Holler E, Kobbe G, Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264-70
   PubMed Web of Science ®Google Scholar
• Alchalby H, Kroger N. Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis. Curr Hematol Malig Rep 2010;5:53-61
   PubMed Web of Science ®Google Scholar
• Ditschowski M, Elmaagacli AH, Trenschel R, Dynamic International Prognostic Scoring sytem scores, pre-transplant therapy and chronic gratf-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica 2012;97:1574-84
   PubMed Web of Science ®Google Scholar
• Santos FPS, Verstovsek S. JAK2 inhibitors: what's the true potential? Blood Rev 2011;25:53-63
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Mesa R, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, JAK inhibition with ruxolitinib vs best available therapy in myelofibrosis. N Engl J Med 2012;366:787-98
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Estrov Z, Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202-9
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood 2012;120:800
   PubMed Web of Science ®Google Scholar
• Cervantes F, Kiladjian JJ, Niederwieser D, Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood 2012;120:801
   Web of Science ®Google Scholar
• Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-91
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119:2721-30
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Caramazza D, George G, Safety and efficacy of CYT387, a JAK 1/ 2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol 2011;29(Suppl):abstract 6614
   Google Scholar
• Pardanani A, Gotlib J, Gupta V, Phase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosis. Blood 2012;120:178
   Web of Science ®Google Scholar
• Verstovsek S, Deeg HJ, Odenike O, Phase 1-2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 2010;116:3082
   Web of Science ®Google Scholar
• Santos FP, Kantarjian HM, Jain N, Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
   PubMed Web of Science ®Google Scholar
• Tefferi A, Verstovsek S, Barosi G, Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Rambaldi A, Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118:2069-76
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55
   PubMed Web of Science ®Google Scholar
• De Angelo DJ, Tefferi A, Fiskus W, A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET), and post-polycythemia vera (PV) myelofibrosis. Blood 2010;116:630
   Web of Science ®Google Scholar
• Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117:6669-72
   PubMed Web of Science ®Google Scholar